AU2015341458B2 - Methods for treatment of cognitive decline - Google Patents

Methods for treatment of cognitive decline Download PDF

Info

Publication number
AU2015341458B2
AU2015341458B2 AU2015341458A AU2015341458A AU2015341458B2 AU 2015341458 B2 AU2015341458 B2 AU 2015341458B2 AU 2015341458 A AU2015341458 A AU 2015341458A AU 2015341458 A AU2015341458 A AU 2015341458A AU 2015341458 B2 AU2015341458 B2 AU 2015341458B2
Authority
AU
Australia
Prior art keywords
thc
patient
administered
age
cognitive decline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015341458A
Other languages
English (en)
Other versions
AU2015341458A1 (en
Inventor
Yosef SARNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2015341458A1 publication Critical patent/AU2015341458A1/en
Application granted granted Critical
Publication of AU2015341458B2 publication Critical patent/AU2015341458B2/en
Priority to AU2020267285A priority Critical patent/AU2020267285A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015341458A 2014-11-03 2015-11-02 Methods for treatment of cognitive decline Ceased AU2015341458B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020267285A AU2020267285A1 (en) 2014-11-03 2020-11-13 Methods for treatment of cognitive decline

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074134P 2014-11-03 2014-11-03
US62/074,134 2014-11-03
PCT/IB2015/058453 WO2016071819A1 (en) 2014-11-03 2015-11-02 Methods for treatment of cognitive decline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020267285A Division AU2020267285A1 (en) 2014-11-03 2020-11-13 Methods for treatment of cognitive decline

Publications (2)

Publication Number Publication Date
AU2015341458A1 AU2015341458A1 (en) 2017-05-25
AU2015341458B2 true AU2015341458B2 (en) 2020-08-13

Family

ID=55908668

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015341458A Ceased AU2015341458B2 (en) 2014-11-03 2015-11-02 Methods for treatment of cognitive decline
AU2020267285A Abandoned AU2020267285A1 (en) 2014-11-03 2020-11-13 Methods for treatment of cognitive decline

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020267285A Abandoned AU2020267285A1 (en) 2014-11-03 2020-11-13 Methods for treatment of cognitive decline

Country Status (7)

Country Link
US (1) US10660872B2 (https=)
EP (1) EP3215148B1 (https=)
JP (1) JP6676062B2 (https=)
CN (1) CN106999467A (https=)
AU (2) AU2015341458B2 (https=)
CA (1) CA2966710A1 (https=)
WO (1) WO2016071819A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11065225B1 (en) * 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
US11446276B2 (en) 2015-07-30 2022-09-20 University Of South Florida Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease
GB2549277B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
BR112020019768A2 (pt) 2018-03-30 2021-01-26 India Globalization Capital, Inc. método e composição para o tratamento de distúrbios do sistema nervoso central (snc)
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2012068516A2 (en) * 2010-11-18 2012-05-24 Pier Pharmaceuticals Low dose cannabinoid medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US7648696B2 (en) 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2012068516A2 (en) * 2010-11-18 2012-05-24 Pier Pharmaceuticals Low dose cannabinoid medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FISHBEIN, M. et al. "Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling" Experimental Brain Research (2012) Vol.221 No.4, pages 437 to 448 *
SARNE, Y. et al. "The dual neuroprotective-neurotoxic profile of cannabinoid drugs" British Journal of Pharmacology (2011) Vol.163 No.7, pages 1391 to 1401 *

Also Published As

Publication number Publication date
CN106999467A (zh) 2017-08-01
JP6676062B2 (ja) 2020-04-08
WO2016071819A1 (en) 2016-05-12
US20170333387A1 (en) 2017-11-23
EP3215148A4 (en) 2018-06-13
EP3215148A1 (en) 2017-09-13
AU2020267285A1 (en) 2020-12-10
EP3215148B1 (en) 2022-04-13
JP2017533276A (ja) 2017-11-09
CA2966710A1 (en) 2016-05-12
US10660872B2 (en) 2020-05-26
AU2015341458A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
AU2015341458B2 (en) Methods for treatment of cognitive decline
EP2037902B1 (en) Cannabinoids for use in the treatment of neuropathic pain
ES2907325T3 (es) Tratamiento de síndrome del cromosoma X frágil y autismo con cannabidiol
JP2021525709A (ja) 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物
GB2432312A (en) Pharmaceutical compositions for the treatment of pain
WO2022103635A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
JP2020514282A (ja) 新規カンナビノイド組成物および使用方法
WO2020006119A1 (en) Methods for treating agitation using dexmedetomidine hydrochloride
Havale et al. Comparative evaluation of pain perception following topical application of clove oil, betel leaf extract, lignocaine gel, and ice prior to intraoral injection in children aged 6–10 years: a randomized control study
WO2020115751A1 (en) Cannabis-based compositions for the treatment of alzheimer's disease and dementia
WO2016044131A1 (en) Method of treating prader-willi syndrome
CN121443298A (zh) 用于治疗持续性脑震荡后症状的苯加兰他敏
Jaggernauth et al. Datura poisoning in Trinidad: a case report
US9877951B2 (en) Method for treating dementia
CN104906501A (zh) 治疗银屑病的中药组分组合物
CN105726557A (zh) 异长春花苷内酰胺在制备治疗肠应激综合征的药物中的应用
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
Miculas et al. Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells 2023, 12, 131
Arasi et al. Pre-Coseasonal vs Perennial Sublingual Immunotherapy for Seasonal Allergens Dosing Regimen: Long-Term Benefits, Adherence, and Cost-Effectiveness—Is There a Difference?
WO2018029685A1 (en) Compositions and methods for treating a fear memory
Subodh Kumar et al. Postinjection delirium/sedation syndrome with Haloperidol Decanoate Injection.
CN106727557A (zh) 一种治疗食道炎的西药组合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired